Tachykinin receptors antagonists: from research to clinic.
Curr Drug Targets
; 7(8): 975-92, 2006 Aug.
Article
in En
| MEDLINE
| ID: mdl-16918326
ABSTRACT
In this chapter it is described how, starting from different approaches and through extensive medicinal chemistry studies, several discovery compounds were optimized and reached the development stage. The first tachykinin receptor antagonist to reach the market in 2003 for chemotherapy-induced emesis has been aprepitant. Other clinical candidates (for central nervous system disorders osanetant, talnetant and saredutant; for irritable bowel syndrome nepadutant and saredutant) are in advanced clinical phase. The clinical studies reported in the literature and the destiny of the clinical candidates, where available, will be reviewed.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Randomized Controlled Trials as Topic
/
Technology, Pharmaceutical
/
Receptors, Tachykinin
Type of study:
Clinical_trials
Limits:
Animals
/
Humans
Language:
En
Journal:
Curr Drug Targets
Journal subject:
TERAPIA POR MEDICAMENTOS
Year:
2006
Document type:
Article
Affiliation country:
Italia